Submissions

Online Submissions

Already have a Username/Password for Cancer Cell & Microenvironment?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

 

Author Guidelines

You must register as an author with this journal before submission. We recommend that you use Yahoo or Gmail as your registration email and future communication email with editorial office. If you do not receive the registration confirmation message within a few minutes of signing up, please check your Spam or Bulk E-Mail folder just in case the confirmation email got delivered there instead of your inbox. If so, select the confirmation message and mark it Not Spam, which should allow future messages to get through.

Article types

  • Research article: It is a substantial novel research study, with a complex story often involving several techniques or approaches. Abstract length: 350 words or fewer (The Abstract must not be structured into separate sections). Article Length: 5000 words or fewer.
  • Brief report: It reports a concise study of high quality and broad interest, but is less substantial than a Research article. Abstract length: 350 words or fewer (The Abstract must not be structured into separate sections).Article Length: 5000 words or fewer.
  • Review: It is an authoritative, balanced and scholarly survey of recent developments in a research field. Abstract length: 350 words or fewer (The Abstract must not be structured into separate sections). Article Length: 5000 words or fewer.
  • Research highlight: It is by invitation only. It is kind of brief review focusing on the paper of exceptional significance written by the same author. It would be better that the research highlight can be combined with proceedings of the author research. Abstract length: 350 words or fewer (The Abstract must not be structured into separate sections). Article Length: 5000 words or fewer.
  • Hypothesis: It should present an untested original hypothesis backed up solely by a survey of previously published results rather than any new evidence. Abstract length: 350 words or fewer (The Abstract must not be structured into separate sections). Article Length: 5000 words or fewer.
  • Commentary: It is opinion pieces consisting of a main point and supporting discussion. These contributions usually pertain to a specific article. Abstract length: Do not require abstracts. Article Length: 5000 words or fewer.
  • Case report: It highlights unique presentations or aspects of disease processes that may expand the differential diagnosis and improve patient care. Abstract length: Do not require abstracts. Article Length: 5000 words or fewer.

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission and peer review.

To facilitate rapid publication, we only accept online submission.

The submission process can be interrupted at any time; when users return to the site, they can carry on where they left off.

Preparing main manuscript text

Word Count:

Abstract length (for Research Articles, Brief reports, Reviews, Research highlights, and Hypotheses): 350 words or fewer (The Abstract must not be structured into separate sections).

Article Length (for all types of articles): 5000 words or fewer (To determine article length, count the body of the manuscript from the start of the Introduction to the end of the Conclusion. The Cover letter, Title page, Abstract, Keywords, Acknowledgments, Conflict of Interest, References, Legends, Illustrations and figures, Tables, and multimedia are not included.)

Please submit your manuscript as a word file that is in a single column format. Manuscripts should be typed in 12-point Time New Roman font with double spacing between lines. Figures and tables should be placed right after the references. Figures must be submitted both within the article to facilitate review and as separate Supplementary files for the layout editor. Each figure must be provided as a separate Supplementary file in the submission process. Files should be titled and numbered consecutively.

Manuscripts for Research Articles and Brief reports submitted to this journal should be divided into the following sections (in this order):

  • Comments for the editor (Cover letter)
  • Title page
  • Abstract
  • Keywords
  • Introduction
  • Materials (or patients) and methods
  • Results
  • Discussion
  • Acknowledgements
  • Conflict of Interest
  • References
  • Legends
  • Illustrations and figures (if any)
  • Tables and captions

Please note that manuscripts for ReviewsResearch highlights, and Hypotheses should have abstracts except for Case reports and Commentaries.

Comments for the editor (Cover letter)

During submission you will be asked to provide a comments for the editor. Use this to explain why your manuscript should be published in the journal, to elaborate on any issues relating to our editorial policies, and to declare any potential competing interests which can benefit our journal and readers.

Title page

The title page should:

  • Provide the title of the article: the title should be brief, informative, of 150 characters or less and should not make a statement or conclusion. 
  • list the full names, institutional addresses and email addresses for all authors
  • indicate the corresponding author
  • Authors' contributions
  • List of abbreviations used(if any)

In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should be specified in this section.

An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.

We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support.

Abstract

The Abstract of the manuscript should not exceed 350 words and must not be structured into separate sections: Background, Methods, Results, and Conclusions. Please minimize the use of abbreviations and do not cite references in the abstract. Trial registration, if your research reports the results of a controlled health care intervention, please list your trial registry, along with the unique identifying number (e.g. Trial registration: Current Controlled Trials ISRCTN73824458). Please note that there should be no space between the letters and numbers of your trial registration number. We recommend manuscripts that report randomized controlled trials follow the CONSORT extension for abstracts.

Keywords

Three to ten keywords representing the main content of the article.

Introduction

The introduction section should be written in a way that is accessible to researchers without specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background to the research and its aims. Reports of clinical research should, where appropriate, include a summary of a search of the literature to indicate why this study was necessary and what it aimed to contribute to the field. The section should end with a brief statement of what is being reported in the article.

Materials (or patients) and methods

The methods section should include the design of the study, the setting, the type of participants or materials involved, a clear description of all interventions and comparisons, and the type of analysis used, including a power calculation if appropriate. Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.

For studies involving human participants a statement detailing ethical approval and consent should be included in the methods section. For further details of the journal's editorial policies and ethical guidelines see 'About this journal'.

For further details of the journal's data-release policy, see the policy section in 'About this journal'.

Results and discussion

The Results and discussion may be combined into a single section or presented separately. Results of statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The Results and discussion sections may also be broken into subsections with short, informative headings.

Conflicting interests

A Conflicting interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial Conflicting interests; they should also reveal any non-financial Conflicting interests that may cause them embarrassment were they to become public after the publication of the manuscript.

Authors are required to complete a declaration of Conflicting interests. All Conflicting interests that are declared will be listed at the end of published articles. Where an author gives no Conflicting interests, the listing will read 'The author(s) declare that they have no Conflicting interests'.

When completing your declaration, please consider the following questions:

Financial Conflicting interests

  • In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
  • Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
  • Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
  • Do you have any other financial Conflicting interests? If so, please specify.

Non-financial Conflicting interests

Are there any non-financial Conflicting interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.

If you are unsure as to whether you, or one your co-authors, has a Conflicting interest please discuss it with the editorial office.

Acknowledgements

Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.

The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

References

Only articles, datasets, clinical trial registration records and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited; unpublished abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and referred to as "unpublished observations" or "personal communications" giving the names of the involved researchers. Obtaining permission to quote personal communications and unpublished data from the cited colleagues is the responsibility of the author. Journal abbreviations follow Index Medicus/MEDLINE.

Any in press articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.

Examples of the reference style

Article within a journal

(Six or fewer authors)

      1. Curtis JM, Hahn WS, Long EK, Burrill JS, Arriaga EA, Bernlohr DA. Protein carbonylation and metabolic control systems. Trends Endocrinol Metab 2012; 23:399-406.

(Seven or more authors)

      2. Hendgen-Cotta UB, Merx MW, Shiva S, Schmitz J, Becher S, Klare JP, et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2008; 105:10256-10269.

Article within a journal supplement
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I. Analysis and assessment of ab initio three-dimensional prediction, secondary structure, and contacts prediction. Proteins 1999; 43(Suppl 3):149-170.

Article in press with DOI
Smith JA, Jones B. Shoot organogenesis from Prunus leaves. Plant Genetics and Transgenics 2006; doi: 10.1008/s001090000065.

Published abstract
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN. Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42:s250.

Article within conference proceedings
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. Stoneham: Butterworth-Heinemann; 1996:16-27.

Book chapter, or article within a book
Schnepf E. From prey via endosymbiont to plastids: comparative studies in dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. New York: Chapman and Hall; 1993:53-76.

Whole issue of journal
Ponder B, Johnston S, Chodosh L (Eds). Innovative oncology. In Breast Cancer Res 1998; 10:1-72.

Whole conference proceedings
Smith Y (Ed). Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996.

Complete book
Margulis L. Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970.

Monograph or book in a series
Hunninghake GW, Gadek JE. The alveolar macrophage. In Cultured Human Cells and Tissues.Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.]

Book with institutional author
Advisory Committee on Genetic Modification. Annual Report. London; 1999.

PhD thesis
Kohavi R. Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University, Computer Science Department; 1995.

Link / URL
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]

Link / URL with author(s)
Corpas M. The Crowdfunding Genome Project: a personal genomics community with open source values [http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-crowdfunding-genome-project-a-personal-genomics-community-with-open-source-values/]

Dataset with persistent identifier
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C (2011). Genome data from sweet and grain sorghum (Sorghum bicolor). GigaScience. http://dx.doi.org/10.5524/100012.

Clinical trial registration record with persistent identifier
Mendelow, AD (2006). Surgical Trial in Lobar Intracerebral Haemorrhage. Current Controlled Trials. http://dx.doi.org/10.1186/ISRCTN22153967

Figure legends

Figure legends should be included after the reference list in the main manuscript text file rather than being a part of the figure file. For each figure, the following information should be provided:

  • Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc.)
  • Short title of figure in sentence case (maximum 15 words - required)
  • Detailed legend (up to 300 words - optional)

e.g.

Figure 7. Effect of nocodazole and ammonium chloride on PCSK9-mediated degradation of the LDLR. HepG2 cells were cultured in media supplemented with nocodazole (20 μg/ml) or ammonium chloride (NH4Cl, 10 mM) for 30 min. The media were then replaced with conditioned media from HepG2 cells transiently transfected with D374Y-PCSK9-FLAG plasmid or with empty plasmid, already containing ammonium chloride or nocodazole, and the incubation was continued for 3 h.

Preparing figures and tables

Upon submission of an article, Figures and tables should be placed right after the references in the WORD file. Figures must be submitted both within the article to facilitate review and as separate Supplementary files for the layout editor. Each figure must be provided as a separate Supplementary file in the submission process. Files should be titled and numbered consecutively. There is no charge for the use of color figures.

  • Multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a single composite file that contains all parts of the figure.
  • Figure titles and legends should be provided in the main manuscript, not in the graphic file.
  • Each figure should be closely cropped to minimize the amount of white space surrounding the illustration. Cropping figures improves accuracy when placing the figure in combination with other elements, when the accepted manuscript is prepared for publication on our site.
  • Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures (or tables) that have previously been published elsewhere. In order for all figures to be open access, authors must have permission from the rights holder if they wish to include images that have been published elsewhere in non-open access journals. If any illustration has been previously published, a copy of the letter of permission from the copyright holder must accompany the illustration. The source of the illustration should be included in the reference list. The figure legend should conclude with "Reprinted with permission" followed by the reference number: e.g. Reprinted with permission [23].

Format

Figures should be provided as JPG, TIF, Photoshop, EPS or high resolution PDF files. Please do not send PowerPoint, MS Word, presentation or paint files as they are inadequate for the creation of high quality images. Much of the information contained in PowerPoint or other file types is lost or skewed in the conversion of images.

Resolution and figure quality

  1. Color, 300 d.p.i. minimum; we prefer RGB for optimal rendering online, and, if possible, recommend that authors use sRGB IEC61966-2.1 when preparing files
  2. Grayscale, 600 d.p.i. minimum for blots and black & white photographs
  3. Line art, 1200 d.p.i. minimum for graphs and illustrations

Chemical schemes

Chemical scheme images, unlike figures, should be included as part of the manuscript.

Scheme legends should not form part of the embedded scheme image, but should appear immediately after the scheme in the text. Please include a legend comprising:

  • Scheme number (in sequence, using Arabic numerals - i.e. Scheme 1, 2, 3 etc.)
  • Short title of scheme, in sentence case (maximum 15 words - required)
  • Detailed legend (up to 300 words - optional)

e.g.

Scheme 1. An overview of glycolysis by which the conversion of glucose to pyruvate is coupled to the production of ATP for energy and NADH for biosynthesis. The entry of glycerol into the glycolytic pathway is also shown. The scheme indicates the hypothetical action of carnosine in the activation of fructose 1,6-bisphosphatase to create a futile, ATP-consuming, cycle which also inhibits glycolytic ATP generation.

Electronic manipulation of images

Enhancement of digital images using image-editing software can increase clarity of figures and is acceptable practice, if carried out responsibly. It is crucial, however, that artefacts are not introduced and the original data is not misrepresented. Details of significant electronic alterations to images must be given in the text of the article. Linear adjustment of the color, contrast or brightness are permitted, but they must be applied to the entire image, not just parts of it.

Non-Native Speakers of English

Researchers who are not native speakers of English who submit manuscripts to international journals sometimes receive negative comments from referees or editors about the English-language usage in their manuscripts, and these problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors to take at least one of the following steps:

  • Have your manuscript reviewed for clarity by a colleague whose native language is English.
  • Use one of the many English language editing services that are available, such as that offered by Nature Publishing Group Language Editing. An editor will improve the English to ensure that your meaning is clear and to identify problems that require your review.

Please note that the use of Editing is at the author's own expense and in no way implies that the article will be selected for peer review or accepted by any journal. The decisions that the editors make based on the quality and suitability of a manuscript for that journal are entirely independent of whether that manuscript has been language-edited by any Language Editing.


 

 

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. I hereby affirm that the submitted manuscript, in whole or in part, is not under consideration or published elsewhere and that all authors have contributed significantly and are aware of and agree to the content of the manuscript and their being listed as an author. We declare that no potential competing interests exist for this manuscript.
  2. I hereby affirm that the submitted manuscript is in the format of Microsoft Word.
  3. I hereby affirm that affiliations [the name of department or division (if any), institution or organization, city, state, zip code and country where the work was done] are provided.
  4. I hereby affirm that the manuscript will be uploaded in the “Step 2. Uploading the Submission” with figures and tables placed right after the references within the article.
  5. I hereby affirm that figures will be uploaded as separate Supplementary files in the “Step 4. Uploading Supplementary Files” in addition to be submitted within the article in Step 2 (to facilitate review). 

    Format

    Figures should be provided as JPG, TIF, Photoshop, EPS or high resolution PDF files. Please do not send PowerPoint, MS Word, presentation or paint files as they are inadequate for the creation of high quality images. Much of the information contained in PowerPoint or other file types is lost or skewed in the conversion of images.

    Resolution and figure quality

    1. Color, 300 d.p.i. minimum; we prefer RGB for optimal rendering online, and, if possible, recommend that authors use sRGB IEC61966-2.1 when preparing files
    2. Grayscale, 600 d.p.i. minimum for blots and black & white photographs
    3. Line art, 1200 d.p.i. minimum for graphs and illustrations
  6. I hereby affirm that in “Step 3. Entering the Submission's Metadata”, names and emails of all of authors will be filled in in order to give respect to their work.
  7. I hereby affirm that reference numbers in the body of manuscript are marked as [1] (in the format of superscript) instead of other forms.
  8. I hereby affirm that in reference list, the author names and journal titles are abbreviated as them shown on PubMed, the issue numbers are removed, and page numbers are completed.
  9. I hereby affirm that in reference list, if there are six or fewer authors, all the names of authors are listed. If there are seven or more authors, the first six authors’ names are listed followed by et al.
  10. I hereby affirm that there are no ethical issues in this manuscript including plagiarism and unreferenced. I agree with the editorial office to use anti-plagiarism software (Crosscheck) to screen my article.
  11. I hereby affirm that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures (or tables) that have previously been published elsewhere. If any illustration has been previously published, a copy of the letter of permission from the copyright holder will be uploaded in “Step 4. Uploading Supplementary Files”. The source of the illustration will be included in the reference list. The figure legend will conclude with "Reprinted with permission" followed by the reference number: e.g. Reprinted with permission [23].
 

Copyright Notice

Authors of articles published in the Journal of Cancer Cell & Microenvironment retain the copyright of their articles. Author can archive pre-print, post-print, and publisher's versions.

Articles published in the Journal of Cancer Cell & Microenvironment are licensed under a Creative Commons Attribution 4.0 International License which allows users including authors of articles to copy and redistribute the material in any medium or format, in addition to remix, transform, and build upon the material for any purpose, even commercially, as long as the author and original source are properly cited or credited.

 

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.